Lung Cancer
News
FDA rejects poziotinib for certain types of lung cancer
The clinical data the company submitted was deemed insufficient for approval.
Conference Coverage
Lung cancer screening pushes 20-year survival rate to 80%
Less than 6% of high-risk smokers get the recommended annual lung cancer screening.
Conference Coverage
Immunotherapeutic target could fill unmet need in NSCLC
Phase 2 clinical trial shows consistent benefits at all levels of PD-L1 expression.
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
From the Journals
Buzz kill: Lung damage looks worse in pot smokers
Emphysema was significantly more common among smokers (75%) than among nonsmokers, a new study finds.
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
From the Journals
Durvalumab combinations show tentative promise in NSCLC
Phase 2 study indicates improved survival and objective response rate when combined with other immunotherapies.
From the Journals
Mutation burden predicts ICI response in lung cancer
Novel biomarker combined with PD-L1 expression could indicate selection of immunotherapy and avoid chemotherapy toxicities in some patients.
Conference Recap
Key Data on Early Non–Small Cell Lung Cancer From ESMO 2022
Osimertinib dosing periods, the use of ctDNA to predict recurrence, and the role of air pollution in promoting lung cancer are among...